Obstetrics and Gynaecology Forum - Volume 18, Issue 4, 2008
Volume 18, Issue 4, 2008
Author Zephne M. Van der SpuySource: Obstetrics and Gynaecology Forum 18 (2008)More Less
Author A. KentSource: Obstetrics and Gynaecology Forum 18, pp 109 –111 (2008)More Less
Umbilical cord blood has been described as medical waste but considerable interest in cord blood has arisen lately because of recent debates and research into fetal physiology. The debates revolve firstly about when the cord should be clamped, and the secondly about whether cord blood should be stored for possible use later.
Author S. AllieSource: Obstetrics and Gynaecology Forum 18, pp 113 –118 (2008)More Less
Diagnosis of JGCTs has in the past been based on history, physical examination, pelvic imaging and measurement of plasma estradiol. Biochemical markers of JGCT include inhibin, Mullerian Inhibitory Substance (MIS) and activin. These markers offer a tool to monitor tumour spread, the effect of therapy, and possible recurrence of JGCT. These various diagnostic tests will be briefly outlined.
Author S. JefferySource: Obstetrics and Gynaecology Forum 18, pp 121 –128 (2008)More Less
A number of studies have shown acupuncture to be a useful adjunct to therapy. Chang et al reported a 77% reduction in urgency and frequency in 77% of their patients versus only 20% in placebo. These findings have been confirmed by Bergstrom et al who also demonstrated reduced incontinence episodes. The most interesting data have emerged from a trial by Emmons et al where they randomised women to acupuncture in bladder specific points versus relaxation point acupuncture.
Source: Obstetrics and Gynaecology Forum 18, pp 131 –136 (2008)More Less
The purpose of this review is to:
- Discuss the difficulties associated with informed consent for epidural analgesia in labour in healthy parturients,
- Outline a reasonable explanation to the patient concerning benefits and risks of epidural analgesia, and
- Present some of the evidence from recent literature which supports the explanation conveyed to the patient.
Trastuzumab (Herceptin) for the diagnosis and treatment of breast cancer : a review : review articleAuthor L.J. Van BogaertSource: Obstetrics and Gynaecology Forum 18, pp 139 –142 (2008)More Less
The emergence of targeted therapy for cancer, and more especially for breast cancer, has created high expectations from patients and oncologists. Trastuzumab, better known as Herceptin, is used for the diagnosis and treatment of tumours carrying the HER-2 oncogene. From the diagnostic point of view, all methods for the assessment of the HER-2 gene or the HER-2 protein have limitations in terms of both technology and cut-off values and have not yet been standardized. Both false positive and false negative assessments are currently not uncommon. The inclusion criteria for treatment with trastuzumab are relatively narrow and the cost per cure is, at present, extremely high. It is therefore essential to have an understanding of the current data about this therapy and of their interpretation.